Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Complete Genomics Initiates Review Of Strategic Alternatives; To Eliminate Jobs

Human genome sequencing company, Complete Genomics Inc (GNOM: Quote) Tuesday announced that it has initiating a number of steps aimed at reducing the cash consumption.

The company stated that it has engaged Jefferies & Company, Inc. to assist it in exploring strategic alternatives.

The company further stated that it intends to focus on development of clinical applications for its whole human genome sequencing service, while continuing to provide high-quality genomes to research customers.

As part of the strategic alternatives, the company plans to eliminate 55 jobs, primarily in field and factory, in Mountain View, California, and other U.S. locations.

The company noted that this employee reduction is expected to be substantially completed during the current quarter ending June 30, 2012. The company further added that restructuring and related costs incurred with this plan are estimated at $1.5 million, most of which will be cash expenditures.

Click here to receive FREE breaking news email alerts for Complete Genomics, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.